DexCom's revised FY24 sales guidance in the Q2 earnings call led to a $18bn valuation reset. Read why I think DXCM stock is a ...

As a leading CGM maker, DexCom is likely to play a significant role in diabetes care for years, possibly decades. Given all ...

Medical device specialist DexCom (NASDAQ: DXCM) is going through a rough patch. The company's shares dropped off a cliff following its second-quarter earnings report. However, zooming out helps ...

San Diego’s Dexcom began sales this week of Stelo, the industry’s first FDA-approved continuous glucose monitor that doesn’t require a prescription. With a two-pack of the biosensor costing ...

I managed to lose seven pounds. SAN DIEGO, September 18, 2024--DexCom, Inc. (NASDAQ: DXCM), the global leader in real-time continuous glucose monitoring (CGM) for people with diabetes, announced ...

Today, Benzinga 's options scanner spotted 8 uncommon options trades for DexCom. This isn't normal. The overall sentiment of ...

Dexcom‘s Stelo glucose monitor is for those people and I’ve found it works pretty well. It’s available today as the first blood sugar monitor for people who don’t have diabetes yet ...

After getting the green light from the FDA back in March, Dexcom today launched its first over-the-counter wearable continuous glucose biosensor, Stelo, in the U.S. market. The device is now ...

DexCom (NASDAQ: DXCM ... and that was one of the biggest reasons to avoid it. But due to the sharp sell-off this year, it's now priced at a much more tenable valuation. And not only is the ...